FOXO4-DRI – 10mg (Proxofim)

FOX04-DRI (10mg) — Research Compound

FOXO4-DRI is a synthetic peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53, a pathway implicated in the survival of senescent cells. By interfering with this binding, FOXO4-DRI is studied for its ability to promote the targeted removal of senescent cells, which contribute to ageing.

Findings from early-stage clinical trials have reported:

• Selective elimination of senescent cells observed in-vivo across ageing research models.
• Improvements in tissue regeneration and functional recovery reported following senescent cell clearance.
• Reductions in systemic inflammatory markers associated with senescence noted in experimental cohorts.
• Observed improvements in physical vitality markers and organ function reported in animal studies.

Researchers study FOXO4-DRI to explore senolytic intervention strategies and the biological mechanisms governing cellular senescence. Its selective action on senescent cells makes it essential for research into longevity and age-related decline.

Available Formats:
This compound is available as a vial of lyophilised powder, or can be ordered in a disposable pen, a reusable pen, or a cartridge for an existing reusable pen system.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use